Dual antiplatelet therapy following percutaneous coronary intervention: Clinical and economic impact of standard versus extended duration recommendations
Dual antiplatelet therapy (DAPT; combination of a P2Y12 inhibitor with ASA is generally given for six to 12 months following percutaneous coronary intervention (PCI) with stenting, with the aim of preventing stent thrombosis and major adverse cardiac and cerebrovascular events (MACCEs). However, deb...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
March 2019, 2019
|
| Series: | CADTH optimal use report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references